Stockscreener 앱 받기
1.91
0.79%
0.015
전일 마감가:
$1.895
열려 있는:
$1.93
하루 거래량:
1.93M
Relative Volume:
0.89
시가총액:
$201.12M
수익:
-
순이익/손실:
$-37.34M
주가수익비율:
-1.4044
EPS:
-1.36
순현금흐름:
$-36.91M
1주 성능:
+2.14%
1개월 성능:
+1.60%
6개월 성능:
+72.07%
1년 성능:
+59.17%
1일 변동 폭
$1.8501
$1.93
1주일 범위
$1.81
$1.95
52주 변동 폭
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
SLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.91 | 236.84M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
Smart tools for monitoring SELLAS Life Sciences Group Inc.’s price actionWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivals2025 Major Catalysts & Real-Time Volume Spike Alerts - newser.com
What data driven models say about SELLAS Life Sciences Group Inc.’s futureMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Using data models to predict SELLAS Life Sciences Group Inc. stock movementJuly 2025 Decliners & Precise Entry and Exit Recommendations - newser.com
What analyst consensus says on SELLAS Life Sciences Group Inc. stock2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
How to integrate SELLAS Life Sciences Group Inc. into portfolio analysis toolsPortfolio Performance Report & High Return Trade Guides - newser.com
Using R and stats models for SELLAS Life Sciences Group Inc. forecastingExit Point & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-09 03:27:21 - newser.com
Published on: 2025-10-09 03:07:14 - newser.com
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Decrease in Short Interest - Defense World
Multi factor analysis applied to SELLAS Life Sciences Group Inc.July 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Using Python tools to backtest SELLAS Life Sciences Group Inc. strategies2025 Dividend Review & Free Accurate Trade Setup Notifications - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock double in coming years2025 Short Interest & Stock Market Timing Techniques - newser.com
Published on: 2025-10-06 05:59:31 - newser.com
SELLAS Extends Times Square Sublease Agreement - TipRanks
Why SELLAS Life Sciences Group Inc. (RXK3) stock benefits from AI revolutionEarnings Risk Summary & Community Consensus Picks - newser.com
Published on: 2025-10-03 03:10:59 - newser.com
Chart based analysis of SELLAS Life Sciences Group Inc. trendsJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Is SELLAS Life Sciences Group Inc. stock bottoming out2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Published on: 2025-10-02 22:11:46 - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 20252025 Volume Leaders & High Conviction Investment Ideas - newser.com
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update - Sahm
SELLAS Life Sciences to host virtual R&D day on AML treatments - Investing.com Nigeria
How Product Roadmap Could Affect Music Broadcast Limiteds Future ValueResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
SELLAS Life Sciences to host virtual R&D day on AML treatments By Investing.com - Investing.com South Africa
What drives SELLAS Life Sciences Group Inc RXK3 stock priceHigh Beta Stocks & Fast Growing Investment Plans - earlytimes.in
SELLAS Life Sciences Group to Host Virtual R&D Day on - GlobeNewswire
Major AML Treatment Updates: SELLAS Life Sciences to Reveal Phase 3 REGAL Results & New Drug Progress - Stock Titan
Published on: 2025-09-30 01:16:34 - newser.com
What high frequency data says about SELLAS Life Sciences Group Inc.Market Activity Recap & Weekly Momentum Picks - newser.com
Published on: 2025-09-29 11:38:19 - newser.com
Published on: 2025-09-29 09:42:54 - newser.com
SELLAS Life Sciences Group Inc RXK3 Stock Analysis and ForecastMomentum Stock Picks & Budget Friendly Growth - earlytimes.in
What drives Deere Company stock priceSector Performance Drivers & Boost Wealth With Growth - earlytimes.in
Can SELLAS Sustain Momentum As GPS Nears Final Readout And SLS009 Moves Forward? - RTTNews
Profit Review: What is the target price for OTIS stockMarket Performance Report & Stepwise Trade Execution Plans - خودرو بانک
Stock Recap: Is SELLAS Life Sciences Group Inc trading at a discountDollar Strength & Growth-Oriented Investment Plans - خودرو بانک
Analysis Recap: Can SELLAS Life Sciences Group Inc stock double in the next yearFed Meeting & Short-Term Swing Trade Alerts - خودرو بانک
Retail Trends: Does SELLAS Life Sciences Group Inc align with a passive investing strategyTrend Reversal & Verified Momentum Stock Watchlist - خودرو بانک
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sellas Life Sciences Group Inc 주식 (SLS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
5.74%
자본화:
|
볼륨(24시간):